NYSE:PFE 5 February 2026 - 11 May 2026

Acuitas Therapeutics has failed in its attempt to shield Pfizer Inc. and BioNTech’s Comirnaty COVID-19 vaccine from GSK’s patent claims, after a Delaware federal judge tossed the case. Judge Gregory Williams sided with GSK’s subsidiaries, dismissing the Acuitas action for lack of subject-matter jurisdiction. In effect, the court said it didn’t have the authority to hear the suit as filed, leaving the broader patent dispute over the high-profile vaccine unresolved. The ruling stops short of saying if Comirnaty actually infringes on GSK’s patents. For Pfizer, that distinction is pressing: the company is working to steer investors’ attention away from its COVID lineup and onto potential growth in cancer, blood thinners, and obesity drugs, especially in the wake of a sharp sales reset during the pandemic.

Pfizer picked up a new short-term catalyst Monday, with the U.S. Food and Drug Administration handing a priority review to its Padcev submission for bladder cancer. The stock gained roughly 0.8%, trading at $27.78 in the afternoon, drawing renewed attention as the company pushes ahead with a wider pipeline. The timing is key: Pfizer is set to post first-quarter results on May 5. Investors will be watching to see how the company tracks against its 2026 revenue guidance—$59.5 billion to $62.5 billion, with COVID products expected to bring in around $5 billion. That forecast already factors in an estimated $1.5 billion impact from loss of exclusivity as older drugs go off patent and generics move in. Pfizer, for its part, has said it plans to run about 20 pivotal studies that could help secure approvals before year-end.

Between April 3 and April 6, a trio of reports drawing on fourth-quarter 13F filings detailed that Aberdeen Group, Raab & Moskowitz Asset Management, and Stratos Wealth Partners each cut back on Pfizer positions—together unloading 740,174 shares. On Monday, Pfizer stock slipped roughly 0.7% to $28.12 in U.S. trading. The timing is what stands out here, not so much the dollar amounts. These latest disclosures shed light on year-end moves as Pfizer makes its pitch to investors, aiming to offset declining COVID sales with a pipeline of new drugs and hopes for more reliable growth.

Pfizer hit a new 52-week high Tuesday, lifted by upbeat analyst notes and a string of pipeline news fueling demand. Shares last changed hands at $27.87 late in the morning, having reached $28.30 earlier—eclipsing the earlier high-water mark of $27.92. This shift is significant: focus is turning away from the fading COVID cash stream at Pfizer. Now, investors are sizing up how quickly oncology, vaccines, and obesity treatments can step in to bridge that gap before legacy drugs lose their edge.

New York, February 7, 2026, 05:48 EST — Market closed Pfizer Inc closed out Friday at $27.22, notching a 2.8% gain. Shares fluctuated from $26.52 to $27.37 throughout the session, with volume hitting roughly 50.7 million shares.

New York, Feb 6, 2026, 08:55 EST — Premarket Pfizer Inc shares slipped roughly 1.1% to $26.49 in premarket action Friday, following Thursday’s close near $26.79.